CoreCap Advisors’s IGM Biosciences IGMS Stock Holding History

CoreCap Advisors’s Portfolio IGMS Stock Details IGMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-2,234	Closed	-$2.57K	–	2987
2025 Q1	$2.57K	Buy	+2,234	New	+$4.16K	﹤0.01%	2286

Other funds holding IGMS

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

CoreCap Advisors's IGMS Position: Q2 2025 in Review

CoreCap Advisors sold out of IGM Biosciences (IGMS) in Q2 2025, closing a stake of 2,234 shares — an estimated $2.57K sold.

CoreCap Advisors first reported a position in IGMS in Q1 2025 and held it in 1 quarter. The position peaked at $2.57K in Q1 2025. 66 funds tracked by Wall St. Rank hold IGMS as of Q2 2025.

CoreCap Advisors reported no remaining IGM Biosciences position as of Q2 2025 after selling out during the quarter.
CoreCap Advisors sold 2,234 IGM Biosciences shares in Q2 2025, an estimated $2.57K.
CoreCap Advisors first reported a position in IGM Biosciences in Q1 2025 and held it in 1 quarter.
CoreCap Advisors's IGM Biosciences position peaked at $2.57K in Q1 2025.
66 funds tracked by Wall St. Rank held IGM Biosciences as of Q2 2025.

Based on CoreCap Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.